| Durand, Christine |
| Active, not recruiting | 2 | 201 | US | Epclusa | University of Pennsylvania, Gilead Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | End Stage Renal Disease | 06/25 | 01/26 | | |
| Active, not recruiting | 2 | 80 | US | Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine | National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University, Sanofi Pasteur, a Sanofi Company | COVID-19, Kidney Transplant | 02/24 | 07/25 | | |
NCT03500315: HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients |
|
|
| Completed | N/A | 209 | US | HIV D+/R+ | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | Hiv | 09/22 | 05/24 | | |
NCT02602262: Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients |
|
|
| Recruiting | N/A | 125 | US | HIV-infected deceased donor organ | Johns Hopkins University, University of Colorado, Denver, Yale University, Georgetown University, Emory University, Rush University Medical Center, University of Illinois at Chicago, Indiana University, University of Maryland, Columbia University, Icahn School of Medicine at Mount Sinai, Weill Medical College of Cornell University, University of Pittsburgh Medical Center, Methodist Health System, Northwestern University, NYU Langone Health, University of Virginia, Washington University School of Medicine, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infection | 07/25 | 07/26 | | |
NCT06263426: Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney) |
|
|
| Recruiting | N/A | 200 | US | HIV D+/R+, HIV D-/R+ | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | Hiv | 09/28 | 09/29 | | |
NCT03734393: HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients |
|
|
| Active, not recruiting | N/A | 80 | US | HIVD+/R+ | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | Hiv | 04/25 | 06/25 | | |
PREVENT-HCV, NCT05653232: Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients |
|
|
| Recruiting | N/A | 120 | US | Prophylaxis (P2W), Transmit and Treat (T&T) | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | HCV | 09/25 | 03/27 | | |
NCT03408106: Prospective Clinical Trial of HIV+ Living Donor Kidney Donation for HIV+ Recipients |
|
|
| Recruiting | N/A | 20 | US | | Johns Hopkins University | HIV Infections | 08/27 | 08/30 | | |
| Aslam, Saima |
| Active, not recruiting | 2 | 400 | US | Pfizer-BioNTech COVID-19 Vaccine 2023-2024, mRNA COVID-19 vaccine, BNT162b2 mRNA COVID-19 vaccine, SARS-CoV-2 RNA vaccine, Comirnaty, Moderna COVID-19 Vaccine 2023-2024, Moderna COVID-19 vaccine, SARS-CoV-2 vaccine, Spikevax, SOC IS Regimen, Standard of Care transplant immunosuppression regimen, Immunosuppression (IS), mycophenolate mofetil (MMF) or equivalent, tacrolimus, SOC IS Reduction, Standard of Care (SOC) transplant immunosuppression regimen, Immunosuppression (IS) Reduction | National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University | Kidney Transplant Recipients, Liver Transplant Recipients | 02/24 | 03/25 | | |
| Active, not recruiting | 2 | 80 | US | Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine | National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University, Sanofi Pasteur, a Sanofi Company | COVID-19, Kidney Transplant | 02/24 | 07/25 | | |
COLT, NCT06075745: Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates |
|
|
| Recruiting | 2 | 416 | US | CMV-MVA Triplex, Placebo for CMV-MVA Triplex | National Institute of Allergy and Infectious Diseases (NIAID) | Liver Transplant | 06/27 | 02/28 | | |
diSArm, NCT05184764: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia |
|
|
| Recruiting | 1/2 | 50 | US, RoW | AP-SA02, Placebo | Armata Pharmaceuticals, Inc., United States Department of Defense | Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus | 12/24 | 03/25 | | |
NCT06263426: Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney) |
|
|
| Recruiting | N/A | 200 | US | HIV D+/R+, HIV D-/R+ | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | Hiv | 09/28 | 09/29 | | |
NCT03734393: HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients |
|
|
| Active, not recruiting | N/A | 80 | US | HIVD+/R+ | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | Hiv | 04/25 | 06/25 | | |
PREVENT-HCV, NCT05653232: Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients |
|
|
| Recruiting | N/A | 120 | US | Prophylaxis (P2W), Transmit and Treat (T&T) | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | HCV | 09/25 | 03/27 | | |
| Esshaki, Yasmeen |
| Active, not recruiting | 2 | 80 | US | Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine | National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University, Sanofi Pasteur, a Sanofi Company | COVID-19, Kidney Transplant | 02/24 | 07/25 | | |
NCT06393101: The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome |
|
|
| Recruiting | 1 | 52 | US | BRC-002, BRC-002 Placebo | University of California, San Diego | Complex Regional Pain Syndrome | 06/29 | 06/29 | | |
